Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT04094961Phase 2Active, not recruiting
- Start
- Sep 2019
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in multiple myeloma (MM). Primary endpoints: Dose Limiting Toxicity at 21 days and Overall Response Rate at 28 days. Started Sep 2019; status: active, not recruiting.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04094961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094961.